NCT03123939 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03123939
Title	Phase III B in Acute Lymphoblastic Leukemia
Recruitment	Completed
Gender
Phase	Phase III
Variant Requirements	No
Sponsors	Novartis Pharmaceuticals
Indications	B-cell acute lymphoblastic leukemia
Therapies	Tisagenlecleucel
Age Groups:	child \| adult
Covered Countries	NOR \| ITA \| FRA \| ESP \| DEU \| CAN \| BEL \| AUT

Filter rows:

Showing 1 to 11 of 11 entries

Facility	City	State	Zip	Country	Details
Novartis Investigative Site	Wien		A 1090	Austria	Details
Novartis Investigative Site	Gent		9000	Belgium	Details
Novartis Investigative Site	Toronto	Ontario	M5G 1X8	Canada	Details
Novartis Investigative Site	Montreal	Quebec	H3T 1C5	Canada	Details
Novartis Investigative Site	Paris Cedex 10		75475	France	Details
Novartis Investigative Site	Paris Cedex		75019	France	Details
Novartis Investigative Site	Frankfurt		60590	Germany	Details
Novartis Investigative Site	Monza	MB	20900	Italy	Details
Novartis Investigative Site	Kyoto		606 8507	Japan	Details
Novartis Investigative Site	Oslo		0424	Norway	Details
Novartis Investigative Site	Esplugues de Llobregat	Barcelona	08950	Spain	Details

Showing 1 to 11 of 11 entries

Filter rows:

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT03123939Clinical Trial Detail